Immunocore Holdings IMCR
NASDAQ IMCR
$32.38 +0.65 (+2.05%)
As of: Nov 10, 2026 · 3:59 PM EST

Immunocore Holdings (IMCR) Notes Payables (2019 - 2023)

Updated

Immunocore Holdings' Notes Payables came in at $1.24 million for Q2 2023.

Analysis

Immunocore Holdings (IMCR) Notes Payables (2019 - 2023) Analysis & Trends

At the end of FY2019, Immunocore Holdings' Notes Payables was $24.63 million.

  • The Q2 2023 figure represents the highest quarterly Notes Payables since Q4 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Immunocore Holdings 1.63 Bn -1.86 Bn 114.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 1.25 Mn
Dec 31, 2019 25.12 Mn
API Access

Immunocore Holdings Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=IMCR&period=max&api_key=YOUR_API_KEY